Removal of iomeprol, a nonionic radiocontrast agent, by hemodialysis with various high performance membrane (HPM) dialyzers was evaluated
in vitro and in patients with end-stage renal failure. Reduction rates of iomeprol
in vitro were 99.9% with a cellulose dicetate (CDA) membrane dialyzer (MELTRA FLUX150), 99.7% with an ethylene vinylalcohol (EVAL) membrane dialyzer (KF20C) and 99.2% with polymethylmethacrylate (PMMA) membrane dialyzer (BK1.6F). Adsorption rates
in vitro were 16.7%, 35.7% and 49.4%, respectively.
In vivo study in 8 hemodialysis patients showed reduction rates of 81.8%, 73.7% and 89.4% with the CDA dialyzer (MELTRA FLU110 and MELTRA FLUX150), 84.5% with the EVAL dialyzer (KF20C), 80.5% and 77.3% with the PMMA dialyzer (BK1.6F), and 84.8% with the cellulose tricetate (CTA) membrane dialyzer (FB210U) after 4 hours of hemodialysis, and 89.9% with the CTA dialyzer (FB210) in hemodiafiltration. Hemodialysis with each HPM dialyzer performed soon after radiological examinations removed iomeprol efficiently and no adverse effects of iomeprol were observed.
It was concluded that iomeprol could be removed efficiently by hemodialysis with the HPM dialyzer and that it could be used safely even in patients with end-stage renal failure.
View full abstract